News / Taiwan / economic_daily
Fortune Life Science Reports 38.6% Revenue Surge in September Driven by New Product Launches
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-10-07
4114
Fortune Life Science announced a 38.6% year-on-year revenue growth for September, fueled by seasonal demand for respiratory drugs and successful market penetration of new treatments.
What Happened
Strong Revenue Growth: Fortune Life Science reported a consolidated revenue of NT$746 million for September, marking a 38.6% year-on-year increase. The company's cumulative revenue for the first nine months reached NT$5.84 billion, representing a 27% growth compared to the same period last year.
Respiratory Segment Momentum: Seasonal demand for respiratory and allergy medications is rising, further bolstered by the launch of the new Synfanas nasal spray. The product has already received regulatory approval and reimbursement pricing, strengthening the company's position in the respiratory market.
Expansion in Women's and Digestive Health: The company is successfully expanding its women's health portfolio, with its new GnRH antagonist for uterine fibroids now available in over 130 medical institutions. Additionally, its new chronic constipation treatment has been adopted by more than 220 hospitals, reflecting strong clinical demand.
Future Outlook: Management expects continued growth as new products gain wider clinical adoption and market penetration. The company remains committed to its strategy of introducing innovative therapies and expanding its regional footprint to solidify its status as a leading pharmaceutical group.